

Short Communication

Beyond Forgotten Memories: Alzheimer's Disease in the Modern Era – Understanding, Prevention, and Future Treatment Strategies

Dielubanza F, Souter E, Pyysalo J, Sakib K, Molinuevo S, Nakane D

Department of Neuroscience and Biomedical Engineering, Iran

***Corresponding Author:** Pyysalo J, Department of Neuroscience and Biomedical Engineering, Iran

Citation: Pyysalo J (2026). Beyond Forgotten Memories: Alzheimer's Disease in the Modern Era – Understanding, Prevention, and Future Treatment Strategies V2 (1)

Copyright: © 2026, Pyysalo J this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received date: April 09 2026; **Accepted date:** April 27, 2026; **Published date:** April 30,2026

Keywords: non-pharmacological interventions, cognitive stimulation, disease-modifying agents, cognitive assessment, devastating disorder, amyloid-beta plaques, mini-mental state examination

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting millions of individuals and placing an enormous burden on families and healthcare systems. Characterized by gradual memory loss, cognitive decline, behavioral changes, and impaired daily functioning, Alzheimer's disease significantly reduces quality of life. The disease is associated with the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of tau protein, leading to neuronal degeneration and brain atrophy. Although the exact cause remains complex, genetic, environmental, and lifestyle factors all contribute to disease development. Early diagnosis through cognitive assessment, neuroimaging, and biomarker analysis has improved clinical management, while advances in pharmacological therapies, including disease-modifying agents, offer new hope for slowing disease progression. Non-pharmacological interventions such as cognitive stimulation, regular physical activity, healthy nutrition, and caregiver support remain essential components of comprehensive care. This article reviews the epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, treatment strategies, preventive measures, and emerging research directions in Alzheimer's disease. Greater public awareness, early intervention, and continued scientific innovation are critical to reducing the global impact of this devastating disorder.

Introduction

Alzheimer's disease (AD) is a chronic, progressive neurological disorder that gradually destroys memory, thinking ability, and behavioral function. First described in 1906 by Alois Alzheimer, the disease has become one of the greatest public health challenges of the twenty-first century due to increasing life expectancy and an aging global population

Alzheimer's disease accounts for approximately 60–80% of all dementia cases and primarily affects individuals

over the age of 65, although early-onset Alzheimer's can occur before this age. The disease progresses slowly over several years, eventually leading to complete dependence for daily activities. Despite extensive research, there is currently no definitive cure, making prevention, early diagnosis, and supportive care crucial.

Epidemiology

Alzheimer's disease affects more than 55 million people worldwide living with dementia, with Alzheimer's representing the majority of these cases. The prevalence continues to rise as populations age.

Major Risk Factors

- Advanced age
- Family history
- Genetic mutations
- Female gender
- Cardiovascular disease
- Diabetes mellitus
- Hypertension
- Obesity
- Smoking
- Physical inactivity
- Low educational attainment
- Traumatic brain injury

Pathophysiology

The hallmark pathological changes include

1. Amyloid-beta Plaques

Abnormal cleavage of amyloid precursor protein (APP) produces amyloid-beta peptides that aggregate into extracellular plaques, disrupting neuronal communication

Journal of Clinical Research, Reports and Trails (JCRRT)

2. Neurofibrillary Tangles

Hyperphosphorylated tau proteins accumulate within neurons, forming intracellular tangles that impair microtubule function and neuronal transport.

3. Neuroinflammation

Activated microglia release inflammatory cytokines that contribute to neuronal injury.

4. Oxidative Stress

Reactive oxygen species damage cellular proteins, DNA, and lipids.

5. Neuronal Loss

Progressive neuronal degeneration causes brain atrophy, particularly within the hippocampus and cerebral cortex.

Clinical Manifestations

Early Stage

- Mild forgetfulness
- Difficulty remembering recent conversations
- Misplacing objects
- Trouble finding words
- Mild confusion
- Difficulty planning tasks

Moderate Stage

- Increased memory impairment
- Personality changes
- Mood swings
- Poor judgment
- Wandering behavior
- Sleep disturbances
- Difficulty recognizing family members

Advanced Stage

- Severe memory loss
- Loss of speech
- Difficulty swallowing
- Loss of mobility
- Complete dependence
- Urinary and fecal incontinence

Diagnosis

Early diagnosis improves patient management.

Clinical Evaluation

- Detailed medical history
- Family history
- Neurological examination
- Cognitive testing

Cognitive Assessment Tools

- Mini-Mental State Examination (MMSE)
- Montreal Cognitive Assessment (MoCA)
- Clock Drawing Test

Laboratory Investigations

- Vitamin B12 levels
- Thyroid function tests
- Complete blood count
- Electrolytes

Neuroimaging

- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Positron Emission Tomography (PET)

Biomarkers

- Cerebrospinal fluid amyloid-beta
- Tau protein
- Plasma biomarkers

Treatment

Although no cure exists, treatment aims to slow progression and improve quality of life

Pharmacological Therapy

Cholinesterase Inhibitors

- Donepezil
- Rivastigmine
- Galantamine

These medications improve communication between neurons by increasing acetylcholine levels.

NMDA Receptor Antagonist

- Memantine

Used in moderate to severe Alzheimer's disease

Disease-Modifying Therapies

Newer anti-amyloid monoclonal antibodies have shown potential to slow disease progression in selected patients with early Alzheimer's disease by reducing amyloid plaque accumulation.


Conclusion

Alzheimer's disease remains one of the most significant neurodegenerative disorders affecting aging populations worldwide. Its multifactorial nature involves complex interactions among genetic susceptibility, abnormal protein accumulation, neuroinflammation, and lifestyle-related risk factors. While current treatments primarily manage symptoms and modestly slow disease progression, ongoing research into biomarkers, targeted therapies, and preventive strategies offers hope for more effective interventions. Public awareness, early diagnosis, comprehensive patient care, and caregiver support remain fundamental to improving quality of life for affected individuals. Continued investment in research and healthcare infrastructure will be essential to address the growing global burden of Alzheimer's disease.

References

1. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. *Journal of Internal Medicine*. 2014;275: 214–228.
2. Kälin AM, Park MTM, Chakravarty MM, Lerch JP, Michels L, Schroeder C, et al. Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. *Frontiers in Aging Neuroscience*. 2017;9.
3. Beheshti I, Demirel H, Farokhian F, Yang C, Matsuda H. Structural MRI-based detection of Alzheimer's disease using feature ranking and classification error. *Computer Methods and Programs in Biomedicine*. 2016;137: 177–193.
4. Pradhan, R.; Petrovic, Z.; Sakib, M.S.; Schröder, S.; Krüger, D.M.; Pena, T.; Diniz, E.; Burckhardt, S.; Schütz, A.L.; Grządzielewska, I.; et al. NeuID, a novel neuron-specific lncRNA, resolves a key epigenetic mechanism linking gene silencing to Alzheimer disease. *bioRxiv* 2025.
5. Pietrzak, A.; Dąbrówka, B.; Popiół, J.; Pękala, E.; Słoczyńska, K. Phase II metabolism in xenobiotic biotransformation: General mechanisms and the underestimated role of microbial systems. *Drug Metab. Rev.* 2026, 58, 1–25.

Journal of Clinical Research, Reports and Trails (JCRRT)



This work is licensed under Creative Commons Attribution 4.0 License
DOI:10/JCRRT/2026/014

Your next submission with

Olites Publishers will reach you through the below assets

- We follow principles of publication led by the Committee on Publication Ethics (COPE).
- Double-blind peer review process which is just as well as constructive.
- Permanent archiving of your article on our website
- Quality Editorial service
- Manuscript accessibility in different formats (PDF, Full Text)
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

Learn more: [Journal of Clinical Research, Reports and Trails- Olites Publishers \(olitespublishing.org\)](https://olitespublishing.org/)